IRVINE, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, announced the completion of the University of Wisconsin Hospital and Clinics' system-wide implementation of Masimo SET pulse oximetry. UW Hospitals and Clinics performed an extensive comparison and thorough evaluation spanning virtually every department and cited precise, continuous SpO2 measurements under demanding conditions as the chief reason for conversion to Masimo SET.
"We were looking for a product with accuracy in the face of difficult monitoring conditions such as patient movement. After evaluating multiple solutions for improving oximetry practice, we chose Masimo SET technology," said Christopher Green, M.D., Medical Director for the American Family Children's Hospital at the University of Wisconsin Hospitals and Clinics.
The University of Wisconsin Hospital and Clinics is a 471-bed facility that ranks among the finest academic medical centers in the United States. With more than 80 outpatient clinics and seven satellite locations, it is one of only two organizations in Wisconsin with designated Level One adult and pediatric trauma centers and is recognized as a national leader in fields such as cancer treatment, pediatrics, ophthalmology, surgical specialties and organ transplantation.
By making the conversion to Masimo, the University of Wisconsin Hospital and Clinics joins other top hospitals in the United States -- including four of the top five -- as listed on the US News & World Report Honor Roll, which have all adopted Masimo SET as their primary pulse oximetry platform. Masimo SET is widely recognized as the most accurate and reliable pulse oximetry technology in the world, clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 readings even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. These studies prove Masimo SET delivers improvements in outcomes, safety and efficiency.
In addition to the University of Wisconsin Hospitals and Clinics' system-wide standardization to Masimo SET pulse oximetry, the conversion also allows UW Hospitals and Clinics' clinicians to utilize Masimo Rainbow SET technology. Masimo Rainbow SET is an upgradable noninvasive blood constituent monitoring platform that is capable of measuring additional blood constituents that previously required invasive procedures. Masimo Rainbow SET's first application is Pulse CO-Oximetry, the first and only technology platform capable of continuously and noninvasively measuring carboxyhemoglobin/carbon monoxide (SpCO), methemoglobin (SpMet), and Pleth Variability Index (PVI), in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate.
By quickly and accurately determining levels of SpCO and SpMet -- two critical dyshemoglobins proven to increase morbidity and mortality in a broad range of clinical settings -- clinicians can accurately determine their patients' true oxygenation status. This allows for more precise and timely diagnosis and treatment.
Pleth Variability Index (PVI) is a noninvasive measurement that quantifies changes in the plethysmographic waveform derived from pulse oximetry, and may provide clinicians with a noninvasive way to monitor functional hemodynamics in their patients. Clinicians who have evaluated PVI believe this technology will prove to be a valuable clinical tool with significant advantages over currently available indicators of changes in functional hemodynamics that are invasive, operator dependent, often inaccurate, and expensive.
Joe E. Kiani, Chairman and CEO of Masimo, stated, "We are proud to partner with The University of Wisconsin Hospitals and Clinics in their efforts to provide their patients with exceptional level of safety and care. This is clearly an organization that is focused on patients and understands the importance of adopting innovative technology to assist them in enhancing the quality of the care they deliver. The opening of the new American Family Children's Hospital, which is designed to give the best and kindest care possible, are examples of UW Hospitals and Clinics' commitment in this area. Their system-wide conversion to Masimo SET technology will further advance patient safety and care throughout this fine organization."
Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.
Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, APOD, and Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corporation. ARM, Acoustic Respiratory Monitoring, BiFi, Rainbow, SpCO, SpMet, PVI, SpHb and Pulse CO-Oximeter are trademarks of Masimo Corporation.
Copyright©2007 PR Newswire.
All rights reserved